LONDON, UK / ACCESSWIRE / June 8, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Property & Casualty Insurance industry. Companies recently under review include American International Group, MGIC Investment, Progressive, and Berkshire Hathaway. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

Earlier this year, stock fluctuations were evident in the Property and Casualty Insurance segment due to evolving consumer demands and heightened competition. In late May, a new report was released, forecasting that the global market would be growing at a compound annual growth rate of 5.77% from 2016 to 2020. Let us see how this is affecting some of the big names in the industry. Gain access to our free research reports on these stocks at:

http://www.activewallst.com/register/

ActiveWallSt.com take a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions.

American International Group Inc. (NYSE: AIG)

New York-based insurance products and services provider, American International Group Inc.’s stock finished Tuesday’s session at $57.06 with a slight correction of 0.40% and a total volume of 5.17 million shares traded. The Company’s shares have advanced 3.67% in the past month and 10.56% in the previous three months. The stock is trading 2.44% above its 50-day moving average and 0.22% above its 200-day moving average. Additionally, shares of American International Group have a Relative Strength Index (RSI) of 55.36. On May 17th, 2016, research firm Wells Fargo upgraded the Company’s stock rating from ‘Market Perform’ to ‘Outperform’.

MGIC Investment Corp. (NYSE: MTG)

On Tuesday, shares in Milwaukee, Wisconsin headquartered private mortgage insurance and ancillary services provider, MGIC Investment Corp., recorded a trading volume of 4.16 million shares. The stock ended the session 0.15% higher at $6.86. The Company’s shares have advanced 2.54% in the last one month. The stock is trading 3.58% below its 50-day moving average. Moreover, shares of MGIC Investment have an RSI of 48.38. On May 10th, 2016, research firm Compass Point reiterated its ‘Neutral’ rating with a decrease of the target price to $8.50 a share from $9 a share for the Company’s stock.

Progressive Corp. (NYSE: PGR)

Shares in Mayfield Village, Ohio headquartered personal and commercial property-casualty insurance, and other specialty property-casualty insurance and related services provider, Progressive Corp., closed the day at $32.53, which was a slight correction of 0.73%. The stock recorded a trading volume of 2.81 million shares. The Company’s shares have gained 5.29% on an YTD basis. The stock is trading 3.33% above its 200-day moving average. Additionally, shares of Progressive have an RSI of 38.14. On June 02nd, 2016, research firm Citigroup downgraded the Company’s stock rating from ‘Neutral’ to ‘Sell’.

Berkshire Hathaway Inc. (NYSE: BRK-B)

At the close, shares in Omaha, Nebraska-based investment manager, Berkshire Hathaway Inc., which engages in the insurance and reinsurance of property and casualty risks business, ended the day at $141.41, which was a slight correction of 0.29%. The stock recorded a trading volume of 2.72 million shares. The Company’s shares have advanced 2.62% in the previous three months and 7.10% since the start of this year. The stock is trading above its 200-day moving average by 4.43%. Furthermore, shares of Berkshire Hathaway have an RSI of 46.95.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440901

Valeant Pharmaceuticals Slumps after cutting its Forecast

LONDON, UK / ACCESSWIRE / June 8, 2016 / ActiveWallSt.com announces its post-earnings coverage on Valeant Pharmaceuticals (NYSE: VRX). The company announced its Q1 FY16 result on Tuesday, June 07, 2016. For Q1 FY16, Valeant posted a loss of $373.7 million, or $1.08 per share, as compared with a profit of $97.7 million, or $0.29 per share in Q1 FY15. Earnings, adjusted for one-time gains and costs, fell to $1.27 a share from $2.05 in Q1 FY15 and well below the Analysts’ consensus estimate of $1.42. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its earnings coverage on VRX. Get all of our free coverage by signing up to http://www.activewallst.com/register/.

The Canadian drug maker reported revenue of $2.37 billion, up 9.3% on y-o-y basis, beating analysts’ consensus estimate of $2.35 billion. Meanwhile, the company’s organic sales declined by $289 million in Q1 FY16. Selling, general and administrative expenses (SG&A) climbed to $620.2 million in Q1 FY16, from $507.9 million in Q1 FY15. Research and development (R&D) costs increased to $103.1 million in Q1 FY16 from $55.8 million in the year ago period.

Valeant also announced a cut in its earnings and revenue forecast for fiscal year 2016. The embattled drug maker now expects earnings of $6.60 to $7.00 per share for FY16, down sharply from its last guidance in March, 2016 for $8.50 to $9.50 per share. The company expects revenue in the range of $9.9 billion to $10.1 billion, below the previous forecast of $11 billion to $11.2 billion announced in March 2016.

Pain-full trail

Shares of the Canadian drug maker plummeted on Tuesday, June 07, 2016, as new CEO Joseph Papa cut FY 16 earnings and sales forecasts, marking a major reset point for the once celebrated company. Valeant’s has grown at a break neck speed for years, fuelled by its strategy of acquiring smaller companies making niche drugs and subsequently raising prices, bypassing the huge research and development investments, typical for the pharmaceutical industry.

The company acquired two heart drugs, Isuprel and Nitropress, and subsequently increased their prices by 525% and 212%, respectively, creating outrage in patients and hospitals relying on these drugs. However, the company’s approach has faced scrutiny from federal prosecutors, lawmakers as well as its own investors as customer raised concerns of the increased drug prices. Valeant is not alone in this practice with companies such as Gilead Sciences (NASDAQ: GILD) and Turing Pharmaceutical also increasing prices of life saving drugs in what many call unethical moves.

Valeant had a close brush with defaulting, as the company underwent federal investigations regarding its business and accounting practices. The company posted long-overdue results from 2015 in April 2016. During the same month, CEO J. Michael Pearson was rebuked in a congressional hearing, where lawmakers accused Valeant of short changing patients to reward the market makers. The Laval, Canada-based company disclosed, last week, that it had been served with default notices from two of its bond holders because of the postponement of the Q1 FY16 earnings report.

The company’s Q1 FY16 earnings results showed how challenging the task at hand will be for Mr. Papa, who joined from generic drugmaker Perrigo Company PLC (NYSE: PRGO) in May, 2016. Two of Valeant’s major sales contributors, dermatology and prescription ophthalmology, have declined by 43% and 30%, respectively. The company has faced resistance from pharmacy benefit managers and health insurers after steeply increasing its drug prices especially in dermatology. Another crucial task falling on Mr. Papa’s shoulders will be to regain the trust of its lenders. The long-term term debt, which skyrocketed under his predecessor, rose to $31.1 billion as of March 31, 2016 from $30.3 billion in December 2015.

Technicals

Valeant’s shares, which recorded a high of $263 in August 2015, fell below $25 post the recent earnings announcement. The stock closed down 14.59% at $24.64 on the NYSE, its lowest close since November 2010. Valeant’s stock has slumped 75.76% since the beginning of the year, while it has down 89.37% in the last 12 months.

—

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440899

Sign of times to come for global luxury goods market

LONDON, UK / ACCESSWIRE / June 8, 2016 / ActiveWallSt.com announces its coverage of the luxury goods industry. The Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on luxury goods retail industry. Register with us now for your free membership at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its industry research coverage. Get all of our research for free by signing up to http://www.activewallst.com/register/.

China’s economic slowdown continues to impact the global luxury goods market. The most recent indication of this has been in the form of a significant pay cut undertaken by British luxury brand Burberry Group PLC’s (LSE: BRBY.L) CEO and Chief Creative Officer, Christopher Bailey. The pay cut was part of the company’s FY2016 results announcement, which saw a revenue decline of 0.3%, the first in the last five years. This follows continued weak performances by other luxury brands such as LVMH Moët Hennessy Louis Vuitton S.E. (Other OTC: LVMHF), Richemont N, and Swiss watchmakers Rolex, TAG Heuer (TAGN) and Swatch (UHR) to name a few. Burberry’s CEO Bailey opted for a 75% cut in total remuneration to GBP1.9 million for FY2016 (ending March) vis-à-vis GBP7.5 million he took home in FY2015.

China controls nearly 20% of the world’s luxury goods market

A weakness in the second-largest economy of the world had a direct and rather immediate impact on the average wealth of Chinese consumers through the stock market crash. Retail investors, who own a majority of China’s stock market, have seen their portfolios erode dramatically in recent months. As such, discretionary spending on luxury goods has taken a back seat. Several large global luxury brands significantly depend on Chinese consumers’ recent penchant for premium products and are now facing the pinch. Global forecasts for luxury goods indicate a meager 2% growth in 2016 with no major signs of recovery until 2020.

Weaker Yuan and curbs on corruption have not helped either

The Chinese government’s decision to devalue the Yuan against a basket of global currencies, especially the US dollar and Euro, has been a setback. A weaker Yuan implies lower value of goods sold in Chinese markets, thus impacting realized revenue for foreign brands. Additionally, the government has cracked the whip on controlling corruption in public parlances, where luxury goods and gifts have been common. Hong Kong and Macau, which have also been strong markets apart from Mainland China, have remained sluggish in their response toward luxury brands.

Middle East unlikely to bring any respite

Regions such as Abu Dhabi and Dubai have emerged as newer markets for luxury goods, given the significant wealth creation over the past decade or so. However, the oil slump of nearly 70% since the past 12 months could be a major headwind for these markets to compensate for the loss that the likes of Burberry and Louis Vuitton have faced in China. Even if oil were to recover, the UAE’s population of a little over 8 million seems too small to move the needle for these brands by any measurable amount.

It appears managing costs and profitability, much like Mr. Bailey’s pay cut, could be the order of the day than material topline growth for luxury brands.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440906

NEW YORK, NY / ACCESSWIRE / June 8, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Avant Diagnostics, Inc. (OTCQB: AVDX).

The report is available here: AVDX June Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

“We are encouraged by management’s ability to close the transaction, which promises to be beneficial for all three entities, given that each were struggling to advance their molecular diagnostic pipelines on their own. The combined company, however, now offers a promising pipeline of four molecular diagnostics initially targeting ovarian cancer, Alzheimer’s disease (AD), multiple sclerosis (MS), and breast cancer, as outlined in the table below. Avant’s acquisition of Theranostics Health will also allow it to gain access to the appropriate CLIA/CAP infrastructure required to commercialize its diagnostics pipeline and its small but growing pharmaceutical services revenue stream.,” commented Ajay Tandon, CEO of SeeThruEquity.

Additional highlights from the note are as follows:

Acquisitions of Amarantus Diagnostics and Theranostics close

On May 12, 2016 Avant announced that it had completed the acquisitions of Amarantus Diagnostics, a wholly-owned subsidiary of neurology and regenerative medicine biotech Amarantus Biosciences Holdings (AMBS), and certain assets and liabilities of Theranostics Health, Incorporated, which develops proteomic technologies for measuring the activation status of key signaling pathways for molecular diagnostics. The acquisitions were announced in January, and closed on the terms that were expected. As part of the deal, former Thernostics Health CEO Glenn Hoke, PhD, will join Avant as Chief Scientific Officer, and Amarantus CEO Gerald Commissiong will joint Avant’s Board of Directors.

Transaction enhances pipeline, transformational for Avant

We are encouraged by the transaction, which should be transformational for Avant, and accelerate the development goals of all three entities. Indeed, while both Amarantus and Avant company were facing obstacles to advancing their molecular diagnostic pipelines on their own, the combined company now truly has a portfolio of molecular diagnostics, with one FDA-approved diagnostic in Theranostics Health’s TheraLink® Assay for breast cancer, and three molecular diagnostics in development, including OvaDx® for ovarian cancer, LymPro Test™ for Alzheimer’s disease (AD), and MSPrecise™ for multiple sclerosis (MS). Importantly, Avant’s acquisition of Theranostics Health will also allow the combined company access to CLIA/CAP infrastructure required to commercialize its diagnostics pipeline, as well as well as its small but growing pharmaceutical services revenue stream.

Maintain price target of $2.97 at this time

We are maintaining our price target of $2.97 for AVDX at this time, as these transactions were contemplated in our initial piece on the company. We are excited about the prospects for the combined company, which now has a compelling pipeline of four molecular diagnostics and a case to raise funds for future development of a molecular diagnostics-focused growth company. We will review our estimates and price target following the issuance of the combined company’s results and outlook.

Please review important disclosures at www.seethruequity.com.

About Avant Diagnostics, Inc.

Avant is a medical diagnostic technology company that specializes in biomarker tests that are being developed in the areas of oncology and neurology. Avant provides personalized medicine diagnostic testing capabilities through its TheraLink® Diagnostic Assays, primarily for breast cancer, to assist clinical oncologists in identify likely responders for roughly 30 FDA-approved drug treatment regimens through its CLIA/CAP. Avant is the leading developer of proteomic technologies for measuring the activation status of key signaling pathways across several different cancer types, including breast, ovarian and pancreatic that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Avant has used these proteomic technologies to support the drug development programs of many of the top biopharmaceutical companies in the world. For more information please visit www.theranosticshealth.com.

Avant is also developing OvaDx® for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma.

Avant’s neurology division owns the rights to MSPrecise™, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test™for Alzheimer’s disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro).

For further information please visit www.AvantDiagnostics.com, or connect with the Company on Facebook and LinkedIn.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 440892

The App is a Creative New Way to Help Drivers Pay Less to Park While Allowing Homeowners to Rent Their Driveways for Extra Income

LOS ANGELES, CA / ACCESSWIRE / June 8, 2016 / Area Parking Inc., a Canadian-based company comprised of three entrepreneurs, recently announced the launch of its new app, AreaParking. The cheaper parking app, which is hailed as the AirBnB for cars, permits homeowners to make a business out of renting their parking spaces to drivers.

According to a New York Times study, about 30 percent of a city’s traffic is attributable to people hunting for parking. In New York City alone, drivers report searching for parking spots for an average of 20 minutes. Although major cities encourage using public transit, bikes, carpools, and other ways to avoid driving extra cars, the AreaParking app helps motorists find and pay for parking in most cities around the country.

With the AreaParking app, owners of private homes and condos can rent their unused parking spaces for a reasonable fee. If they plan ahead, drivers can book spaces at a reduced cost through the app as well. Although the team received an innovation grant and the app has already been approved on the App Store and Google Play, Area Parking Inc. is seeking the necessary funds to continue running a referral program that gives $100 to every user that refers five friends to the app.

At this time, Area Parking Inc. has taken its campaign to Kickstarter in order to raise the money. In exchange for donations, the Area Parking Inc. team is offering credits, t-shirts, and the opportunity to make suggestions to improve the app.

“Our referral program allows users to spread the word of our app and get rewarded for it,” said the team. “We wish to implement in a few countries one by one in a very strategic fashion.”

Individuals interested in learning more about AreaParking and its features can visit the app’s IndieGogo page for additional information.

About AreaParking:

AreaParking is a mobile application that offers owners of private homes and condos with parking space the opportunity to rent their parking and make an income with a free or unused space. A driver can plan or book a space at a cheaper cost and hassle free right from the app. Since drivers’ and space owners’ needs are both met, AreaParking is in the business of “sharing economies.” For more information, please visit https://goo.gl/sGeWWT.

Contact:

Derek Warren
admin@rocketfactor.com
(949) 555-2861

SOURCE: Area Parking Inc.

ReleaseID: 440761

SUNRISE, FL / ACCESSWIRE / June 8, 2016 / U.S. STEM CELL, Inc. (OTCQB: USRM) – The Chief Science Officer of U.S. Stem Cell Inc, Kristin Comella, and a team of researchers published a paper in the Journal of Translational Medicine. The team investigated the effects of the intra-myocardial implantation of stromal vascular fraction (SVF) in patients with chronic ischemic cardiomyopathy. A total of 28 patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered into the scar region using the MyoCath® catheter delivery system in patients who had experienced a previous myocardial infarct. The subjects were then monitored for adverse events, ejection fraction via echocardiogram and 6-minute walk test (6MWT) over a period of 6 months. The average ejection fraction was 29% at baseline and significantly increased to 35% at both 3 and 6 months. Patients walked an average of 349 meters at baseline and demonstrated a statistically significant improvement at 3 and 6 months’ post treatment of more than 80 meters. More importantly, the procedure demonstrated a strong safety profile with no severe adverse events or complications linked to the therapy.

Kristin Comella highlighted that at U.S. Stem Cell, “We are focused on bringing new regenerative medicine therapies to patients and completing clinical trials is key to understanding the safety and effectiveness of these treatments. The positive results of this study demonstrate the exciting potential of cellular medicine. We are thrilled that our work has been recognized in a prestigious peer reviewed journal.”

A copy of the paper can be found at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890248/pdf/12967_2016_Article_918.pdf

About U.S. Stem Cell, Inc.

U.S. Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (U.S. Stem Cell Training, Vetbiologics, and U.S. Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue,” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

Media Contact:
U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500
usstemcell@us-stemcell.com

SOURCE: U.S. Stem Cell, Inc.

ReleaseID: 440908

VANCOUVER, BC / ACCESSWIRE / June 8, 2016 / Evrim Resources Corp. (TSXV: EVM) (“Evrim” or the “Company”) announces exploration results and the resumption of exploration activity at the Company’s 100% owned Cerro Cascaron project in Chihuahua, Mexico. A large, zoned, and high grade gold vein field has been defined at Cerro Cascaron and the next phase of exploration is aimed at mapping the extent of the system and defining drill targets. Cerro Cascaron is a low sulphidation epithermal gold target located in the dissected volcanic terrains of the Sierra Madre Occidental in Chihuahua, approximately 55 kilometres southeast of Goldcorp Inc.’s past-producing El Sauzal gold mine.

Cerro Cascaron Exploration Highlights

• The Cerro Cascaron vein field is 4 kilometres by 2.5 kilometres and open in all directions
• The veining has been mapped over 900 vertical metres with strong textural and geochemical zonation
• The upper 380 metres contains bonanza grade vein mineralization with abundant visible gold. Rock chip samples grade from <0.005 grams per tonne (“g/t”) to 1,670 g/t gold
• The lower 520 metres are characterized by silver and base metal rich veins with rock chip samples grading from <0.5 g/t to 599 g/t silver
• Mapping has defined competent quartz veins up to 1.5 metres wide and quartz breccia veins/quartz healed faults and stockwork zones up to 25 metres wide
• Tourmaline rich breccias and veins with high grade gold values from 0.565 g/t to 39.7 g/t gold are present at the lowest elevations

“The Cerro Cascaron project is an indication that the mineral endowment in Mexico continues to produce untested high quality exploration targets,” commented Alain Charest, Evrim Resources’ Vice President Exploration for Mexico. “In six months Evrim’s exploration team has transformed Cerro Cascaron from an unexplored concession to a highly prospective low sulphidation epithermal gold target.”

About the Cerro Cascaron Project

The 69 square kilometre Cerro Cascaron project covers a historic Colonial-era mining district that contains numerous gold and gold-silver prospects. The property hosts significant veining with high gold and silver grades that has never been drilled or evaluated by modern exploration techniques.

Mapping to date has focused on the eastern part of the concession which contains multiple north-south trending veins including the Serpiente Dorada, C, P, and M Veins. These north-south trending veins are cut by east-west and northeast-southwest trending structures including the J, R and DC Veins. The upper levels of the veining occur at the contact between the Upper and Lower Volcanic Sequence. This setting and mineralization is similar to many epithermal deposits in the Sierra Madre Occidental, including Fresnillo PLC’s La Cienega Mine in Durango with historic production of 2.1 million ounces gold and 34.8 million ounces silver.

Figure 1 – Map of Cerro Cascaron vein field with interpreted cross section

To view an enhanced version of this graphic, please visit:
https://www.accesswire.com/uploads/20969_enhanced1.jpg

The epithermal textures in the upper levels of the vein field include white to green coloured drusy, colloform banded quartz and quartz after bladed calcite with visible gold. In addition, these upper levels of veining exhibit bonanza gold grades with high gold to silver ratios and elevated antimony and silver geochemistry and this level is interpreted to be a low sulphidation zone.

The epithermal textures in the lower levels of the vein field include white drusy to crystalline quartz with sericite, pyrite, chalcopyrite, sphalerite and galena. These lower levels are defined by high silver grades, low gold to silver ratios and elevated base metal, molybdenum, bismuth, tellurium, and arsenic geochemistry. This level is interpreted as an intermediate sulphidation zone within the system.

At the lowest elevations, the T Prospect consists of tourmaline and quartz veins within a hydrothermal breccia with high gold grades; four samples returned 0.565 g/t to 39.7 g/t gold. The zone is at the lowest elevations mapped to date and has elevated copper, molybdenum and bismuth geochemistry. The prospect is hosted within hornfelsed and propylitic rocks near a granodiorite.

To view Cerro Cascaron maps and photographs, please visit www.evrimresources.com.

Cerro Cascaron Exploration Program

Exploration is underway with three objectives; to define the extent of the open pit, bulk tonnage target, to delineate oreshoot targets along the high grade veins and to extend mapping beyond the currently defined vein field.

The additional work will focus on the open pit target at the Serpiente Dorada zone where the two significant breccia veins intersect and are surrounded by a broad zone of narrow sheeted quartz, hematite, manganese and gold epithermal veins. Trenching and channel sampling will define the extent and grade of the target area.

Detailed vein mapping, trench and channel sampling at the C, P, M and D Veins within the low sulphidation zone will define the width, grades and strike length of the veins.

This program is planned to define drill targets and extend the mapping beyond the current known veining.

Figure 2 – Open pit, bulk tonnage target area and high grade oreshoot targets.

To view an enhanced version of this graphic, please visit:
https://www.accesswire.com/uploads/20969_regular2.jpg 

About Evrim Resources

Evrim Resources is a mineral exploration company whose goal is to participate in significant exploration discoveries supported by a sustainable business model. The Company is well financed, has a diverse range of quality projects and a database in Mexico and portions of southwestern United States. The existing projects, and generation of quality exploration targets and ideas, are advanced through option and joint venture agreements with industry partners to create shareholder value. Evrim’s business plan also includes royalty creation utilizing the Company’s exploration expertise and existing projects.

On Behalf of the Board
EVRIM RESOURCES CORP.

Paddy Nicol
President & CEO

To find out more about Evrim Resources Corp., please contact Paddy Nicol, President or Charles Funk, VP New Opportunities & Exploration at 604-248-8648, or visit www.evrimresources.com.

Forward Looking Information

This news release includes certain statements that may be deemed “forward looking statements.” All statements in this news release, other than statements of historical facts, that address events or developments that Evrim Resources Corp. (the “Company”) expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward looking statements. Factors that could cause the actual results to differ materially from those in forward looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by securities laws, the Company undertakes no obligation to update these forward looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Evrim Resources Corp.

ReleaseID: 440909

Shot by Photographer Eric Chapman, N A U T I Features Attractive Models in Seaside-Themed Settings

LOS ANGELES, CA / ACCESSWIRE / June 8, 2016 / Eric Chapman, a Massachusetts-based fashion photographer, recently unveiled his latest idea to the public, a coffee-table book called N A U T I. The book, which features high-fashion models on the seaside, gives readers an insider look at nautical life in its most popular forms.

 

When finished, N A U T I will be a nine by 12-inch book with 75 to 100 thick pages of matte-finish paper. About 70 percent of the models will be shot in a studio setting and on location, while another 15 percent will be of nautical locations such as Martha’s Vineyard, Jamestown RI, Cape Cod MA, and Boston MA. The remaining pages will be 10 percent original paintings and five percent custom nautical graphic patterns.

At this time, Chapman has taken his idea to Kickstarter, where he seeks the funds necessary to complete his coffee table photo book. The money raised will go towards the project’s necessities such as printing and shipping; hiring models, hair, and makeup artists; photo equipment, and painting supplies. In exchange for the public’s support, Chapman is offering a wide variety of perks like personal video messages, launch party invitations, signed copies of N A U T I, outtakes and more.

“Everything you will see in N A U T I has been photographed, painted, and designed by me,” said Chapman.

“Photography and art are two of the biggest influences in my life and I would love nothing more than to share my work with the world. With the experience and connections I have in the industry, I know I can make it happen.”

Individuals interested in learning more about Eric Chapman and N A U T I can visit the book’s Kickstarter page for additional information.

About N A U T I:

The beauty of a coffee-table book is its ability to be many things at once: a piece of art, a statement accessory, a posh paperweight, countless hours’ worth of reading material, or even a chic drink coaster. N A U T I is the perfect addition to any house or apartment coffee table. Artsy, edgy, and controversial, this book will encourage curiosity with every turn of the page. For more information, please visit https://goo.gl/ecfttJ.

Contact:

April Dunn
admin@rocketfactor.com
(949) 555-2861

SOURCE: Eric Chapman

ReleaseID: 440897

Winners will be honored at the 2016 SVUS Red Carpet Awards Ceremony Dinner in San Francisco

BOCA RATON, FL / ACCESSWIRE / June 8, 2016 / Gerry David, President and CEO of Celsius Holdings, Inc. (OTCQX: CELH), the creator and marketer of Celsius®, the world’s first negative calorie drink backed by clinical science, has been named one of only 25 Gold Winners recognized globally in the prestigious CEO World Awards®. David was selected as “The Leader” in the CEO of the Year category, recognized for his crucial role at the helm of the rapidly-expanding brand. Winners will be honored in San Francisco on Monday, June 27, 2016 during the annual SVUS Red Carpet Awards Ceremony Dinner.

The CEO World Awards were created to honor and generate industry-wide recognition for the achievements and positive contributions of CEOs spanning every business arena across the globe. More than 40 judges comprised of a broad spectrum of industry voices from around the world, and over 200 CEOs were nominated. Their average scores determined the 2016 CEO World Award winners.

Mr. David’s broad experience in manufacturing, product development, marketing, sales, regulatory, supply chain and finance provides the leadership a company requires as it grows aggressively both domestically and internationally. At the young age of 27, Mr. David opened his first startup, growing the company to cover six states before going public. He has over 20 years of experience in the technology sphere, having held executive roles at IBM, Honeywell and GTE, and more than 21 years of experience in consumer products with companies such as HSN Direct, Oxyfresh and Vitarich Labs. He has personally led three startups, overseen turnarounds at five companies and successfully managed businesses spanning 72 countries.

“It’s an honor to be named a winner by CEO World Awards for this esteemed industry and peer recognition,” said Gerry David. “This award not only speaks to Celsius’ ability to stand out among a saturated beverage market through exciting initiatives that break through the clutter and put Celsius at the forefront, but is also a testament to our employees’ commitment, work ethic and dedication to the brand, without which this recognition would not have been possible.”

Celsius is available nationwide at retailers across all channels, including supermarkets, convenience stores, nutritional stores, mass merchants, health clubs, spas, gyms, specialty stores, the military and e-commerce websites.

About Celsius Holdings, Inc.

Celsius Holdings Inc. (OTCQX: CELH) is a global nutritional science based company, founded in April 2004. Celsius® negative calorie drink is available in the form of ready to drink and powder formulas powered by MetaPlus™, a proprietary blend of quality ingredients including Green Tea with EGCG, Ginger, Taurine, Gaurana, and B and C vitamins. Backed by multiple published university studies, drinking Celsius before exercise has been proven to help burn more body fat, burn 100 calories and more per serving and provide healthy energy.

Celsius comes in seven delicious flavors, carbonated and non-carbonated, and also in powder stick formulas that can be mixed with water. Celsius has no preservatives, no aspartame, no high fructose corn syrup, no artificial flavors or colors and is very low in sodium. The Celsius line of products is vegan and kosher certified, Gluten Free, and sugar free. The first university study was conducted in 2005, and additional studies from the University of Oklahoma were conducted over the next five years. All studies were published in peer reviewed journals and validated the unique benefits Celsius provides to the consumer.

For more information, please visit www.celsius.com.

About the CEO World Awards

CEO World Awards are an annual industry and peers recognition program honoring CEOs and Companies of all types and sizes in North America, Europe, Middle-East, Africa, Asia-Pacific, and Latin-America. The Annual CEO World Awards is part of the SVUS Awards® recognition program from Silicon Valley in the United States of America which also includes other programs such as Consumer World Awards, Customer Sales and Service World Awards, Golden Bridge Awards, Globee Fastest Growing Private Companies Awards, Info Security PG’s Global Excellence Awards, Network Products Guide’s IT World Awards, Pillar World Awards, PR World Awards, and Women World Awards.

Learn more about The CEO World Awards at www.ceoworldawards.com.

Forward-Looking Statements

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings’ future results of operations and/or financial position, or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would,” or similar words. You should not rely on forward-looking statements since Celsius Holdings’ actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations affecting our business; and other risks and uncertainties discussed in the reports Celsius Holdings has filed previously with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.

Investor Relations:

Hayden IR
Brett Maas
(646) 536-7331
brett@haydenir.com
or
Cameron Donahue
(651) 653-1854
cameron@haydenir.com

SOURCE: Celsius Holdings, Inc.

ReleaseID: 440874